Hematological toxicity of combined 177lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up

Neuroendocrinology

Volumn 99, Issue 2, 2014, Pages 108-117

  Kesavan, Murali ^a   Claringbold, Phillip G ^a   Turner, J Harvey ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Capecitabine; Gastroenteropancreatic neuroendocrine tumor; Myelotoxicity; Peptide receptor radionuclide therapy; Temozolomide

Indexed keywords

CAPECITABINE; HEMOGLOBIN; OCTREOTATE LU 177; RADIOPHARMACEUTICAL AGENT; TEMOZOLOMIDE; UNCLASSIFIED DRUG; LUTETIUM 177; OCTREOTIDE; 177LU-OCTREOTATE; ANTINEOPLASTIC AGENT; DACARBAZINE; DEOXYCYTIDINE; FLUOROURACIL;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL STUDY; DRUG DOSE INCREASE; FEMALE; FOLLOW UP; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NEUTROPHIL COUNT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOISOTOPE THERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOCYTE COUNT; THROMBOCYTOPENIA; TUMOR DIFFERENTIATION; VERY ELDERLY; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; HEMOGLOBIN BLOOD LEVEL; INCIDENCE; PHASE 1 CLINICAL TRIAL (TOPIC); RADIATION DOSE; TREATMENT OUTCOME; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLINICAL TRIAL; DIGESTIVE SYSTEM NEOPLASMS; DRUG COMBINATION; DRUG EFFECTS; HEMATOLOGIC DISEASES; INTESTINAL NEOPLASMS; NEUROENDOCRINE TUMORS; NEUTROPHIL; PANCREATIC NEOPLASMS; PATHOLOGY; STOMACH NEOPLASMS; THROMBOCYTE;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC AGENTS; BLOOD PLATELETS; DACARBAZINE; DEOXYCYTIDINE; DIGESTIVE SYSTEM NEOPLASMS; DRUG THERAPY, COMBINATION; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HEMATOLOGIC DISEASES; HUMANS; INCIDENCE; INTESTINAL NEOPLASMS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; NEUTROPHILS; OCTREOTIDE; PANCREATIC NEOPLASMS; RADIOPHARMACEUTICALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STOMACH NEOPLASMS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 84905052174     PISSN: 00283835     EISSN: 14230194     Source Type: Journal    
DOI: 10.1159/000362558     Document Type: Article

References (17)

1. Giandomenico V, Modlin IM, Ponten F, et al: Improving the diagnosis and management of neuroendocrine tumors: utilizing new advances in biomarker and molecular imaging science. Neuroendocrinology 2013; 98: 16-30.
2. Imhof A, Brunner P, Marincek N, et al: Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [ 90 Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 2011; 29: 2416-2423.
3. Marincek N, Jorg AC, Brunner P, et al: Somatostatin- based radiotherapy with [ 90 YDOTA]- TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study. J Transl Med 2013; 11: 17.
4. 177Lu-DOTA 0 , Tyr 3 ] octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005; 23: 2754-2762.
5. 177Lu-DOTA 0 , Tyr 3 ] octreotate: toxicity, efficacy and survival. J Clin Oncol 2008; 26: 2124-2130.
6. Falconi M, Bartsch DK, Eriksson B, et al: ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: welldifferentiated pancreatic non-functioning tumors. Neuroendocrinology 2012; 95: 120-134.
7. 177Lu-DOTA]-TOC in neuroendocrine cancers. J Clin Oncol 2012; 30: 1100-1106.
8. 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2011; 38: 302-311.
9. 177Lu octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors. Cancer Biother Radiopharm 2012; 9: 561-569.
10. 177Lu-octreotate. J Nucl Med 2013; 54: 1857-1861.
11. Rinke A, Muller H-H, Schade Brittinger C, et al: Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol 2009; 27: 4656-4663.
12. Yao JC, Shah MH, Ito T, et al: Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 514-523.
13. Pavel ME, Hainsworth JD, Baudin E, et al: Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo- controlled, phase 3 study. Lancet 2011; 378: 2005-2012.
14. Raymond E, Dahan L, Raoul JL, et al: Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 64: 501-513.
15. Turner JH: Outpatient therapeutic nuclear oncology. Ann Nucl Med 2012; 26: 289-297.
16. NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. June 14, 2010. http://evs.nci.nih.gov/ftp1/CTCAE/About.html.
17. Strosberg J, Fine RL, Choi J, et al: First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011; 117: 268-275.